Maravai LifeSciences Investor Presentation 2023

Maravai LifeSciences presented its 2023 investor outlook covering nucleic acid production, biologics safety testing, and cell and gene therapy capabilities. The presentation discusses COVID-19 revenue dynamics, customer growth strategies, facility investments, and the Alphazyme acquisition to strengthen mRNA and advanced therapy manufacturing services.